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ABSTRACT
Introduction: Carbapenem-resistant Pseudomonas aeruginosa (CRPA) has been isolated with 
increasing frequency in Brazilian hospitals. Since June 2003, its detection in a teaching hospital in 
the city of Florianópolis, Brazil, has increased. This study aimed to investigate the minimal inhibitory 
concentration (MIC), presence of Metallo-β-lactamase (MβL) and a possible clonal relationship 
among the isolates. Methods: The study included 29 CRPA and seven isolates with reduced 
susceptibility. The MIC was determined by agar-dilution. Detection of MβL was performed by 
Double Disk Sinergism (DDS) and Combined Disk (CD). The MβL gene was verified by PCR 
and nucleotide sequence analysis. Epidemiological typing was performed by pulsed-field gel 
electrophoresis. Results: Among the 29 carbapenem-resistant isolates, polymyxin B presented 
100% susceptibility and piperacillin/tazobactam 96.7%. Seventeen (62%) strains were verified as 
clonal (A clone) and among these, six isolates indicated phenotypically positive tests for MβL and 
harbored the blaSPM-1 gene. The first CRPA isolates were unrelated to clone A, harbored blaIMP-16 and 
were phenotypically positive only by CD. Conclusions: The spread of a high-level of resistance 
clone suggests cross transmission as an important dissemination mechanism and has contributed 
to the increased rate of resistance to carbapenems. This study emphasizes the need for continuous 
surveillance and improved strategies for infection control in this institution.
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RESUMO
Introdução: O isolamento de Pseudomonas aeruginosa resistente aos carbapenêmicos (PARC) tem 
sido cada vez mais frequente nos hospitais brasileiros. O presente estudo investigou a concentração 
inibitória mínina (CIM), a presença de metalo-β-lactamases (MβL), e uma possível relação clonal 
entre PARC isoladas entre junho de 2003 a junho de 2005, em um hospital escola na cidade de 
Florianópolis, Brasil. Métodos: O estudo incluiu 29 PARC e sete isolados com suscetibilidade 
reduzida. A CIM foi determinada por diluição em ágar. A detecção de MβL foi realizada por 
sinergismo de duplo disco (SDD) e disco combinado (DC). Genes para MβL foram pesquisados 
por PCR e confirmados pela análise da sequência de nucleotídeos. A tipagem epidemiológica foi 
realizada por gel de eletroforese em campo pulsátil. Resultados: Entre os 29 isolados resistentes 
aos carbapenêmicos, 100% apresentaram suscetibilidade a polimixina B, e 96,7% a piperacilina/
tazobactam. Dezessete (62%) destes isolados pertenciam a um mesmo clone (clone A); entre estes, 
seis isolados apresentaram testes fenotípicos positivos para MβL e carreavam o gene blaSPM-1. O 
primeiro isolado PARC não foi relacionado ao clone A, carreava o gene blaIMP-16  e foi fenotipicamente 
positivo somente por DC. Conclusões: A propagação de um clone com alto nível de resistência 
sugere a transmissão cruzada como um importante mecanismo de disseminação e tem contribuído 
para o aumento nos níveis de resistência aos carbapenêmicos. Este estudo enfatiza a necessidade de 
vigilância contínua e melhoramento nas estratégias de controle de infecção nesta instituição. 
Palavras-chaves: Pseudomonas aeruginosa. Resistência aos carbapenêmicos. Infecção nosocomial.
Pseudomonas aeruginosa,  one of the main 
microorganisms that cause nosocomial infections1,2, 
is known for its intrinsic resistance to a range of 
antimicrobial agents3. It can also become resistant 
to all commercially available antimicrobial agents 
by developing numerous resistance mechanisms2,3. 
For two decades, carbapenems were considered an 
excellent therapeutic choice for such infections. 
However, Pseudomonas aeruginosa resistant to this 
class of antimicrobial agent has been isolated with 
increasing frequency in Brazilian hospitals, mainly in 
Intensive Care Units4,5. Studies suggest that infection 
caused by carbapenem-resistant Pseudomonas 
aeruginosa (CRPA) significantly increases mortality 
in critically ill patients6,7. The most common 
form of resistance is through either lack of drug 
penetration (i.e. porin mutations and efflux pumps) 
and/or carbapenem-hydrolyzing β-lactamases, 
such as metallo-β-lactamases (MβL)3. It has been 
suggested that in the absence of MβL, high imipenem 
resistance rates in isolates can show great genomic 
variability, which can be associated with continuous 
selection of resistant mutants8. However, in many 
geographic regions of Brazil, this has been associated 
with the dissemination of an epidemic clone that 
produces SPM MβL9. Clinical isolates of CRPA 
have been increasingly detected since June 2003 
in a teaching hospital in the City of Florianópolis, 
Santa Catarina, Brazil. The aim of this study was to 
investigate the minimum inhibitory concentration 
(MIC) for antipseudomonas antimicrobials, the 
presence of MβL and a possible clonal relationship 
among isolates.
METHODS
Bacterial isolates 
This study included clinical isolates of CRPA 
from patients at the University Hospital, Federal 
University of Santa Catarina (HU/UFSC), between 
June 2003 and June 2005. Twenty-nine isolates 
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showed high-level resistance to carbapenems and seven isolates 
presented reduced susceptibility. The samples came mainly from 
patients in the Intensive Care Unit (32.8%) and Internal Medicine 
Unit III (19.8%), but isolates from other inpatient units were also 
collected. The bacteria were identified by conventional biochemical 
tests in accordance with the published recommendations10. 
Antimicrobial susceptibility test 
The MIC of bacterial isolates was determined for each of nine 
antimicrobial agents (amikacin, ceftazidime, aztreonam, cefepime, 
ciprofloxacin, imipenem, meropenem, piperacillin/tazobactam 
and polymyxin B), performed by the agar dilution method and 
interpreted in accordance with CLSI11. Pseudomonas aeruginosa 
ATCC 27853 was used for quality control. 
Phenotypic detection of metallo-β-lactamase
Two methods were used to screen the isolates for MβL detection: 
the double-disk synergy test12 (DDS), using 2-mercaptopropionic 
acid (MPA) (Sigma, Steinheim, Germany), and the ceftazidime 
disk (CAZ - 30μg), placed 20 mm away; and the combined disk13 
(CD) test, using disk of imipenem (IMI - 10µg) with and without 
ethylenediaminetetraacetic acid (EDTA) (930μg) (Invitrogen, 
SanDiego, USA). DDS test results were considered positive if the 
growth inhibition zone increased or if a ghost zone appeared, while 
the CD test was considered positive if the increase in zone diameter 
was ≥ 7mm. SPM-1-producing Pseudomonas aeruginosa and IMP-
producing Acinetobacter baumannii were used as positive controls. 
Molecular detection of metallo-β-lactamase genes
All isolates were tested for the presence of blaSPM-1, blaIMP, 
blaVIM genes by polymerase chain reaction (PCR) using primers, 
as previously described14. Total DNA was obtained by boiling 
bacterial cells. PCR conditions used for blaSPM and blaVIM were 
performed according to Toleman et al15, while the conditions 
used to detect the blaIMP gene were previously described by Gales 
et al16. Positive controls for blaSPM-1, blaVIM-1 and blaIMP genes were 
run simultaneously.
Sequencing
Amplicons obtained from an SPM-producing isolate and from 
the IMP-producing isolate were sequenced, using the set of primers 
previously described. The amplification products for the blaIMP-1 
and blaSPM-1 genes were purified using a GFX-TM PCR purification 
kit (Amersham Bioscience, Piscataway, USA). The sequences were 
identified with MegaBACETM (Amersham Bioscience, Piscataway, 
USA), analyzed with ChromasPro version 1.33 (Technelysium Pty 
LTDA), and compared with GenBank database sequences using 
BLAST tool (http://www.ncbi.nih.gov/BLAST).
Pulsed-field gel electrophoresis (PFGE)
DNA of all isolates was prepared as described previously17 
and cleaved with SpeI (10U) (Fermentas, Glen Burnie, USA) at 
37°C. Electrophoresis was performed on a CHEF - DRIII (Bio-rad 
Laboratories, Hercules, USA) for 23h at 6V/cm at 12ºC and pulse 
times from 5 to 60 s. The gels were analyzed with Gel-Pro Analyzer 
4.0 and NTSYS 2.02 software. Clusters of possibly related isolates 
were identified using the Dice similarity coefficient and unweighted 
pair-group method with arithmetic averages (UPGMA). Identical 
isolates were assigned the same capital letter. Isolates with more than 
90% similarity were assigned as a subtype of the major type, which 
was designated with the same capital letter followed by an Arabic 
number (e.g. A1, A2, A3, A4).
Pseudomonas aeruginosa resistant to carbapenems (imipenem 
and meropenem), were isolated from the urinary tract (37.9%), 
bloodstream (31%), respiratory tract (13.8%) and from other 
anatomical sites (17.3%). All of them were susceptible to polymyxin 
B, and 96.7% to piperacillin/tazobactam. Susceptibility to the 
other antimicrobial agents tested was infrequent, 6% to aztreonam 
and cefepime; 10% to ciprofloxacin; 16.7% to amikacin and 43% 
to ceftazidime. Six out of the seven isolates that showed reduced 
susceptibility to carbapenems presented reduced susceptibility only 
to meropenem (MIC 8μg/mL), while the remaining isolate showed 
reduced susceptibility to both carbapenems tested (meropenem and 
imipenem) (MIC 8μg/mL). 
Isolates that showed intermediate susceptibility to carbapenems 
presented negative results in the phenotypic test for MβL. When the 
29 carbapenem-resistant isolates were tested, seven MβL-producing 
isolates were detected by the CD test and six isolates by DDS. 
When PCR was used to detect MβL genes, six of the seven isolates 
phenotypically positive for MβL yielded a 650 bp product compatible 
with a fragment amplified from blaSPM-1, while one isolate yielded a 
590 bp product compatible with a fragment amplified from blaIMP. 
The remaining isolates did not generate PCR products. The results of 
PCR for blaSPM-1 confirmed the findings of both phenotypic methods 
FIGURE 1 - Dendrogram and electrophoresis showing profiles of PFGE 
restriction fragments cleaved with Spel enzyme from 29 isolates of carbapenem-
resistant Pseudomonas aeruginosa isolated in a teaching hospital in Florianópolis, 
Santa Catarina, Brazil, during the period from July 2003 to July 2005.
369
Rev Soc Bras Med Trop 43(4):367-371, jul-ago, 2010
DISCUSSION
TABLE 1 - Genotypic and phenotypic data for the characterisation of 29 isolates of carbapenem-resistant Pseudomonas aeruginosa used in this study.
                                                                                                                          MIC(µg/mL)                                                                         MβL detection* 
                         Isolates                                                                                           Antimicrobials**                                                                 phenotypic         genotypic     PFGE
N Data of isolation Unit*** AMI CAZ AZT CPM CIP IMI MER PTZ POL DDS CD MβL  profile
1 06/2003 ICU >512 >256 16 256 32 32 128 16/4 0.25 - + IMP-16 B
2 09/2003 IM III 32 64 32 16 >32 8  128 16/4 0.50 - - - D
3 03/2004 IM II >512 >256 16 >256 32 >128 >128 16/4 0.25 + + SPM-1 A3
4 03/2004 SUI >512 8 128 32 32 32 128 16/4 0.50 - - - A1
5 04/2004 ICU >512 >256 16 >256 32 >128 >128 8/4 0.50 +    + SPM-1 A1
6 05/2004 IM II 64 4 64 16 16 16 64 8/4 0.50 - - - G
7 09/2004 ICU 128 8 64 16 16 16 64 16/4 0.50 - - - E
8 10/2004 ICU 2 1 4 2 <1 32 128 <1/4 0.25 - - - J
9 10/2004 IM III >512 >256 16 >256 32 >128 >128 32/4 0.25 + + SPM-1 A3
10 11/2004 SU I 16 2 16 16 8 32 64 8/4 0.25 - - - F
11 11/2004 SU I >512 >256 16 >256 32 >128 >128 8/4 0.50 + + SPM-1 A1
12 11/2004 ICU 2 1 2 2 <1 16 64 <1/4 0.50 - - - I
13 01/2005 SU II 4 8 8 8 <1 16 16 16/4 0.50 - - - L
14 01/2005 IMI 8 >256 16 >256 32 >128 >128 8/4 0.25 + + SPM-1 A1
15 01/2005 IM III >512 >256 >256 >256 32 32 128 128/4 0.25 - - - A1
16 01/2005 IM III >512 32 32 16 32 32 64 32/4 0.25 - - - A5
17 02/2005 ICU >512 8 128 128 32 32 128 16/4 0.12 - - - A3
18 03/2005 ICU 8 16 8 8 <1 16 16 16/4 0.25 - - - H
19 03/2005 IM III >512 32 32 16 32 32 64 32/4 0.25 - - - A5
20 03/2005 ICU >512 8 64 32 32 32 128 8/4 0.25 - - - A1
21 03/2005 IM III >512 >256 16 256 32 32 128 16/4 0.25 - - - A1
22 04/2005 ICU >512 8 128 64 32 32 128 16/4 0.12 - - - A1
23 04/2005 ICU >512 64 64 16 16 32 128 16/4 0.25 - - - A1
24 05/2005 IM III >512 16 64 32 32 32 128 8/4 0.25 - - - A1
25 05/2005 IM III >512 8 64 32 32 32 128 8/4 0.25 - - - J
26 05/2005 E 128 8 32 16 16 16 64 16/4 0.25 - - - C
27 05/2005 E 8 16 64 16 <1 32 >128 16/4 0.25 - - - K
28 06/2005 E >512 32 32 32 32 32 64 16/4 0.50 - - - A4
29 06/2005 IM II >512 >256 16 >256 32 >128 >128 8/4 0.50 + + SPM-1 A2
*(-) not found.
**AMI: amikacin, CA Z: ceftazidime, A ZT: aztreonam, CPM: cefepime, CIP: ciprofloxacin, IMI: imipenem, MER : meropenem, PTZ: piperaci l l in/tazobactam, 
POL: polymyxin.
***ICU: Intensive Care Unit, General medicine, IM III: Internal Medicine Unit III, IM II: Internal Medicine Unit II, IM I: Internal Medicine Unit I, Surgical, SUII: Surgical Unit II, SUI: Surgical 
Unit I, E: Emergency.
used (DDS and CD). The positive isolate for blaIMP by PCR was also 
positive in the CD test, but produced a false negative result in DDS. 
Sequencing of the respective PCR products confirmed that the genes 
implicated were blaSPM-1 and blaIMP-16 (Table 1).
PFGE genotyping of the samples, isolated at the HU/UFSC 
during the period studied (Figure 1), revealed the presence of a 
clone (clone A) that included 17 (62%) of the 29 samples of CRPA 
and comprised all SPM-1 positive strains. The remaining eight were 
unrelated, except for two strains that were clonal (clone J).  
IMP-16 producing Pseudomonas aeruginosa was the first strain 
resistant to carbapenems at the HU/UFSC and was not related to 
any other isolates. 
The first Pseudomonas aeruginosa representatives of A clone 
(subtype A3), isolated in March 2004, harbored blaSPM-1 gene. 
In the following months, five additional positive blaSPM-1 isolates 
belonging to A clone subtypes were isolated in different units of 
the hospital. 
Pseudomonas aeruginosa was one of the main pathogens involved 
in nosocomial infection during the study period. Carbapenems 
were considered an excellent therapeutic choice for treatment of 
these infections; however, the increasing resistance to these agents 
verified in the institution (13% in 2003, 32% in 2004 and 44% in 
2005) was concerning.
All isolates were susceptible to polymyxin B, currently used for 
empirical treatment of Pseudomonas aeruginosa infections in severely 
ill patients, particularly those in Intensive Care Units in Brazilian 
hospitals. Piperacillin-tazobactam was also a viable alternative 
treatment (96.7% susceptibility) and all isolates producing MβL were 
susceptible to this drug. According to previous studies, piperacillin-
tazobactam could be a reliable treatment option for MβL-producing 
Pseudomonas aeruginosa when used appropriately7,18,19. Expression 
of high-level resistance to various antimicrobial agents may involve 
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